Stock comparison
Corcept Therapeutics
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CORT
Corcept Therapeutics
Market cap
$6.46B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CORT | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 68D | 72B | RMD |
| Benjamin Graham | 86C | 75B | CORT |
| Philip Fisher | 64C | 75B | RMD |
| Peter Lynch | 32F | 58C | RMD |
| Joel Greenblatt | 47D | 47D | Tie |
| Charlie Munger | 60C | 69B | RMD |
| Terry Smith | 68C | 73B | RMD |
Side-by-side metrics
| Metric | CORT | RMD |
|---|---|---|
| Market cap | $6.46B | $30.18B |
| P/E (TTM) | 122.0x | 19.6x |
| EV/EBIT | 131.9x | 17.1x |
| ROIC (TTM) | -1.23% | 19.63% |
| Gross margin | 98.25% | 61.69% |
| Net margin | 6.23% | 27.44% |
| Revenue CAGR 5y | 20.1% | 12.64% |
| EPS CAGR 5y | -0.52% | 30.73% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CORT leads on
- Debt / Equity0.0xvs 0.1x+88%
- Gross margin98.25%vs 61.69%+37%
- Revenue CAGR 5y20.1%vs 12.64%+37%
RMD leads on
- ROIC (TTM)19.63%vs -1.23%+106%
- EPS CAGR 5y30.73%vs -0.52%+102%
- Dividend yield1.14%vs 0.0%+100%
- EV/EBIT17.1xvs 131.9x+87%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.